Infinity Pharmaceuticals, Inc. (INFI) Tuesday said fourth-quarter loss narrowed to $32.93 million or $0.68 per share from $46.98 million or $1.15 per share in the same period last year. On average, nine analysts polled by Thomson Reuters expected the company to report a loss of $0.87 per share for the quarter.
In last intraday trading, Infinity Pharmaceuticals, Inc. (NASDAQ : INFI), Biotechnology company’s stock fell -5.64%, closing the day at $9.53, after vacillating among $9.42 and $10.20. The stock’s 52-week range is $23.68 – $8.40 with -52.96%change compare to 17.96% of S&P 500.
ImmunoGen, Inc. (IMGN), a developer of targeted anticancer therapeutics, reported Friday that its second-quarter net income was $3.81 million or $0.04 per share, compared to a net loss of $24.39 million or $0.29 per share last year. On average, 15 analysts polled by Thomson Reuters expected loss of $0.18 per share for the quarter.
The price of ImmunoGen, Inc. (NASDAQ : IMGN), Biotechnology company, fell $-0.82 (or -6.94%) to $11.00 in intraday trading post fluctuating among $10.90 and $11.735. At the closing bell, shares in ImmunoGen, Inc. recorded a trading volume of 1154329 shares as compared to its average volume of 939367 shares. Total market capitalization of company is $943.9 million.
Fluidigm Corporation (FLDM) Monday said first-quarter loss widened to $15.4 million or $0.57 per share from $3.6 million or $0.14 per share in the same period last year. Analysts, based on consensus, expected the company to report a loss of $0.31 per share for the quarter. Analysts’ estimates typically exclude special items.
Fluidigm Corporation (NASDAQ : FLDM), Diagnostics & Research company’s shares after opening at $27.48 hit its intraday high price of $27.86 moreover then closed at $25.68 while shares fell -7.43%. The stock is currently trading with difference of $-23.78 and $+9.96 from this year’s highest and lowest prices. Fluidigm Corporation recorded $-1.096 earnings (per share).
Dendreon Corp. (DNDN), a biotechnology firm focused on cancer treatments, Thursday reported first-quarter net loss of $36.38 million or $0.24 per share, narrower than $72.01 million or $0.48 per share in the prior year.
On a non-GAAP basis, net loss per share was $0.15, while the firm posted $0.36 per share last year.
In last intraday trading, Dendreon Corp. (NASDAQ : DNDN), Biotechnology company’s stock fell -6.48%, closing the day at $2.02, after vacillating among $2.02 and $2.19. The stock is currently trading with difference of $-3.36 and $+0.21 from this year’s highest and lowest prices. Dendreon Corp. recorded $-1.712 earnings (per share).